• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

2016 年至 2021 年美国监狱丁丙诺啡使用趋势。

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.

机构信息

National Clinician Scholars Program at the Corporal Michael J. Crescenz Veterans Affairs Medical Center, University of Pennsylvania, Philadelphia.

Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia.

出版信息

JAMA Netw Open. 2021 Dec 1;4(12):e2138807. doi: 10.1001/jamanetworkopen.2021.38807.

DOI:10.1001/jamanetworkopen.2021.38807
PMID:34905010
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8672225/
Abstract

This cross-sectional study examines trends in the use of buprenorphine among incarcerated individuals in the US.

摘要

这项横断面研究考察了美国被监禁个体中丁丙诺啡使用的趋势。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1516/8672225/7aa02bac23a5/jamanetwopen-e2138807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1516/8672225/7aa02bac23a5/jamanetwopen-e2138807-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1516/8672225/7aa02bac23a5/jamanetwopen-e2138807-g001.jpg

相似文献

1
Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021.2016 年至 2021 年美国监狱丁丙诺啡使用趋势。
JAMA Netw Open. 2021 Dec 1;4(12):e2138807. doi: 10.1001/jamanetworkopen.2021.38807.
2
Opioid use disorder incidence and treatment among incarcerated pregnant women in the United States: results from a national surveillance study.美国监禁孕妇阿片类药物使用障碍发生率和治疗情况：一项全国性监测研究结果。
Addiction. 2020 Nov;115(11):2057-2065. doi: 10.1111/add.15030. Epub 2020 Mar 18.
3
Association Between the Number of Certified Buprenorphine Prescribers and the Quantity of Buprenorphine Prescriptions: Evidence from 2015 to 2017.丁丙诺啡认证处方医生数量与丁丙诺啡处方量之间的关联：2015年至2017年的证据
J Gen Intern Med. 2019 Nov;34(11):2313-2315. doi: 10.1007/s11606-019-05165-6.
4
Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.美国监狱中阿片类药物使用障碍治疗药物在新冠疫情期间的供应变化
Drug Alcohol Depend. 2022 Mar 1;232:109291. doi: 10.1016/j.drugalcdep.2022.109291. Epub 2022 Jan 11.
5
An ethical analysis of medication treatment for opioid use disorder (MOUD) for persons who are incarcerated.对被监禁者阿片类药物使用障碍（MOUD）药物治疗的伦理分析。
Subst Abus. 2020;41(2):150-154. doi: 10.1080/08897077.2019.1695706. Epub 2019 Dec 4.
6
Methadone and buprenorphine treatment in United States jails and prisons: lessons from early adopters.美国监狱中美沙酮和丁丙诺啡治疗：早期采用者的经验教训。
Addiction. 2021 Dec;116(12):3473-3481. doi: 10.1111/add.15565. Epub 2021 May 25.
7
Availability of Medications for Opioid Use Disorder in U.S. Jails.美国监狱中用于阿片类药物使用障碍的药物供应情况。
J Gen Intern Med. 2023 May;38(6):1573-1575. doi: 10.1007/s11606-022-07812-x. Epub 2022 Nov 14.
8
The Evolving Medicolegal Precedent for Medications for Opioid Use Disorder in U.S. Jails and Prisons.美国监狱中阿片类药物使用障碍药物治疗的不断演变的法医学先例
J Am Acad Psychiatry Law. 2021 Dec;49(4):545-552. doi: 10.29158/JAAPL.200127-20. Epub 2021 Aug 2.
9
Trends In Buprenorphine Prescribing By Physician Specialty.医生专业的丁丙诺啡处方趋势。
Health Aff (Millwood). 2019 Jan;38(1):24-28. doi: 10.1377/hlthaff.2018.05145.
10
Adoption of the 275-patient buprenorphine treatment waiver for treating opioid use disorder: A state-level longitudinal analysis.采用 275 例患者丁丙诺啡治疗豁免治疗阿片类药物使用障碍：一项州级纵向分析。
Subst Abus. 2020;41(2):259-268. doi: 10.1080/08897077.2019.1635959. Epub 2019 Jul 11.

引用本文的文献

1
A self-assessment of opioid use disorder services at a Pacific Northwest County jail.对太平洋西北地区一个县监狱的阿片类药物使用障碍服务的自我评估。
Subst Abuse Treat Prev Policy. 2025 Aug 13;20(1):31. doi: 10.1186/s13011-025-00667-5.
2
Non-fatal opioid overdose and unmet need for medications for opioid use disorder among recently incarcerated people who inject drugs.近期入狱的注射吸毒者中，非致命性阿片类药物过量使用及阿片类物质使用障碍药物需求未得到满足的情况。
Drug Alcohol Depend. 2025 May 1;270:112634. doi: 10.1016/j.drugalcdep.2025.112634. Epub 2025 Feb 25.
3
Extended-release buprenorphine induction in opioid non-tolerant incarcerated individuals.

本文引用的文献

1
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence.丁丙诺啡维持治疗与安慰剂或美沙酮维持治疗用于阿片类药物依赖的比较
Cochrane Database Syst Rev. 2004(3):CD002207. doi: 10.1002/14651858.CD002207.pub2.
阿片类药物不耐受的在押人员中缓释丁丙诺啡的诱导治疗
Drug Alcohol Depend Rep. 2024 Jul 20;12:100261. doi: 10.1016/j.dadr.2024.100261. eCollection 2024 Sep.
4
Framework for opioid use disorder screening and diagnosis in carceral settings.监狱环境中阿片类物质使用障碍筛查与诊断框架
Int J Drug Policy. 2024 Dec;134:104627. doi: 10.1016/j.drugpo.2024.104627. Epub 2024 Oct 30.
5
Disparities in Medication Use for Criminal Justice System-Referred Opioid Use Disorder Treatment.刑事司法系统转介的阿片类药物使用障碍治疗中药物使用的差异。
JAMA Health Forum. 2024 Sep 6;5(9):e242807. doi: 10.1001/jamahealthforum.2024.2807.
6
Access to Services for Pregnant People With Opioid Use Disorder in Jails in the United States.美国监狱中阿片类药物使用障碍孕妇的服务获取情况。
J Correct Health Care. 2023 Aug;29(4):299-307. doi: 10.1089/jchc.22.03.0023. Epub 2023 May 26.
7
Allocation of federal funding to address the opioid overdose crisis in the criminal legal system.分配联邦资金以解决刑事司法系统中的阿片类药物过量危机。
J Subst Use Addict Treat. 2023 Jul;150:209064. doi: 10.1016/j.josat.2023.209064. Epub 2023 May 6.
8
Estimated Use of Prescription Medications Among Individuals Incarcerated in Jails and State Prisons in the US.美国监狱和州立监狱中被监禁个体的处方药使用估计数。
JAMA Health Forum. 2023 Apr 7;4(4):e230482. doi: 10.1001/jamahealthforum.2023.0482.
9
Public Health and Prisons: Priorities in the Age of Mass Incarceration.公共卫生与监狱：监禁时代的重点议题。
Annu Rev Public Health. 2023 Apr 3;44:407-428. doi: 10.1146/annurev-publhealth-071521-034016. Epub 2022 Dec 21.
10
Medication for opioid use disorder treatment continuity post-release from jail: A qualitative study with community-based treatment providers.出狱后治疗阿片类药物使用障碍的药物治疗连续性：一项基于社区的治疗提供者的定性研究。
Int J Drug Policy. 2022 Dec;110:103803. doi: 10.1016/j.drugpo.2022.103803. Epub 2022 Aug 11.